[go: up one dir, main page]

JO3014B1 - مثبط متغاير الحلقات للإنزيم المحدد لدرجة التخليق الحيوي للأحماض الدهنية غير المشبعة - Google Patents

مثبط متغاير الحلقات للإنزيم المحدد لدرجة التخليق الحيوي للأحماض الدهنية غير المشبعة

Info

Publication number
JO3014B1
JO3014B1 JOP/2009/0075A JOP20090075A JO3014B1 JO 3014 B1 JO3014 B1 JO 3014B1 JO P20090075 A JOP20090075 A JO P20090075A JO 3014 B1 JO3014 B1 JO 3014B1
Authority
JO
Jordan
Prior art keywords
stearoyl
coa desaturase
heterocyclic inhibitors
derivatives
heterocyclic
Prior art date
Application number
JOP/2009/0075A
Other languages
English (en)
Inventor
Fonarev Julia
Fu 4-Jianmin
Hou 5-Duanjie
Zhang 10-Zaihui
Chowdhury Sultan
Sun Shaoyi
Kodumuru Vishnumurthy
Jia Qi
Pokrovskaia 8-Natalia
Dales Natalie
Original Assignee
Xenon Pharmaceuticals Inc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40740143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3014(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xenon Pharmaceuticals Inc, Novartis Ag filed Critical Xenon Pharmaceuticals Inc
Application granted granted Critical
Publication of JO3014B1 publication Critical patent/JO3014B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بمشتقات ذات الحلقات المختلفة التي تعدل نشاط ستياريل CO-A ديساتيوراز . طرق لاستعمال مثل المشتقات لتعديل نشاط ستياريل CO-A ديساتيوراز و تركيبات صيدلية تتضمن مثل هذه المشتقات التي تشتمل ايضا على ذلك
JOP/2009/0075A 2008-02-20 2009-02-19 مثبط متغاير الحلقات للإنزيم المحدد لدرجة التخليق الحيوي للأحماض الدهنية غير المشبعة JO3014B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3013708P 2008-02-20 2008-02-20

Publications (1)

Publication Number Publication Date
JO3014B1 true JO3014B1 (ar) 2016-09-05

Family

ID=40740143

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0075A JO3014B1 (ar) 2008-02-20 2009-02-19 مثبط متغاير الحلقات للإنزيم المحدد لدرجة التخليق الحيوي للأحماض الدهنية غير المشبعة

Country Status (28)

Country Link
US (2) US8049016B2 (ar)
EP (1) EP2245029B1 (ar)
JP (2) JP5507474B2 (ar)
KR (1) KR101584826B1 (ar)
CN (1) CN102007123B (ar)
AR (1) AR070429A1 (ar)
AU (1) AU2009216769A1 (ar)
BR (1) BRPI0907826A2 (ar)
CA (1) CA2715947C (ar)
CL (1) CL2009000381A1 (ar)
CO (1) CO6290655A2 (ar)
CR (1) CR11629A (ar)
CU (1) CU23890B1 (ar)
EA (1) EA022797B1 (ar)
EC (1) ECSP10010411A (ar)
HN (1) HN2010001647A (ar)
IL (1) IL207578A (ar)
JO (1) JO3014B1 (ar)
MA (1) MA32150B1 (ar)
MX (1) MX2010009158A (ar)
MY (1) MY156317A (ar)
NZ (1) NZ587350A (ar)
PE (1) PE20091473A1 (ar)
SV (1) SV2010003650A (ar)
TW (1) TWI457338B (ar)
UA (1) UA105000C2 (ar)
WO (1) WO2009103739A1 (ar)
ZA (1) ZA201005725B (ar)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR062360A1 (es) 2006-08-15 2008-11-05 Novartis Ag Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa
CN101595105B (zh) * 2006-12-20 2013-01-23 诺瓦提斯公司 作为scd抑制剂的2-取代的5元杂环化合物
KR101584826B1 (ko) 2008-02-20 2016-01-18 노파르티스 아게 스테아로일-ＣｏＡ 데새투라제의 헤테로시클릭 억제제
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
WO2011039358A1 (en) * 2009-10-01 2011-04-07 Novartis Ag Pyrazole derivatives which modulate stearoyl-coa desaturase
UA114323C2 (uk) * 2012-05-11 2017-05-25 Еббві Інк. Інгібітори nampt
EA026432B1 (ru) 2012-05-21 2017-04-28 Новартис Аг Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
JP2019529342A (ja) * 2016-09-08 2019-10-17 四川科倫博泰生物医薬股▲フン▼有限公司Ｓｉｃｈｕａｎ Ｋｅｌｕｎ−Ｂｉｏｔｅｃｈ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 新型２−アミドチアゾール誘導体、及びその製造方法と用途
CN110099898B (zh) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
WO2018129403A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics Methods for the treatment of neurological disorders
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
CN112312913B (zh) 2018-03-23 2024-03-08 詹森药业有限公司 化合物和其用途
AU2020212034A1 (en) 2019-01-24 2021-09-16 Janssen Pharmaceutica Nv Compounds and uses thereof
WO2021083182A1 (zh) * 2019-10-28 2021-05-06 南京明德新药研发有限公司 一种尿酸促排剂及其合成方法和其在医药上的应用
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
BR112022011917A2 (pt) 2019-12-20 2022-09-06 Tenaya Therapeutics Inc Fluoroalquil-oxadiazois e seus usos
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH590267A5 (ar) * 1972-10-04 1977-07-29 Ciba Geigy Ag
US4058617A (en) 1972-10-04 1977-11-15 Ciba-Geigy Corporation Imidazoles and pharmaceutical composition
IL44282A (en) 1974-02-25 1979-01-31 Ciba Geigy Ag 1-(1-alkyl-4(5)nitro-imidazol-2-yl)-2-oxo-tetrahydroimidazole derivatives, their manufacture and pharmaceutical compositions containing them
AU9648098A (en) 1997-10-27 1999-05-17 Takeda Chemical Industries Ltd. Adenosine a3 receptor antagonists
EP1205478A4 (en) 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
WO2001074811A2 (en) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
EP1354603A1 (en) 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
US20050080113A1 (en) 2001-06-11 2005-04-14 Shigenori Ohkawa Medicinal compositions
US20090192191A1 (en) 2004-01-09 2009-07-30 Braj Bhushan Lohray Substituted hydroxamic acid derivatives as tnf inhibitors
EP1621539A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP2316458A1 (en) * 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
MX2007003325A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
BRPI0611187A2 (pt) * 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
ATE486862T1 (de) * 2006-06-05 2010-11-15 Novartis Ag Organische verbindungen
AR062360A1 (es) 2006-08-15 2008-11-05 Novartis Ag Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa
JP2010501567A (ja) 2006-08-24 2010-01-21 ノバルティス アクチエンゲゼルシャフト 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物
EP2066664A1 (en) * 2006-09-22 2009-06-10 Novartis AG Heterocyclic organic compounds
GB0621452D0 (en) * 2006-10-27 2006-12-06 Ucl Business Plc Therapy for liver disease
CN101595105B (zh) * 2006-12-20 2013-01-23 诺瓦提斯公司 作为scd抑制剂的2-取代的5元杂环化合物
RU2010137862A (ru) * 2008-02-13 2012-03-20 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Производное бициклоамина
KR101584826B1 (ko) 2008-02-20 2016-01-18 노파르티스 아게 스테아로일-ＣｏＡ 데새투라제의 헤테로시클릭 억제제
PE20110136A1 (es) 2008-06-27 2011-03-17 Novartis Ag Compuestos organicos

Also Published As

Publication number Publication date
BRPI0907826A2 (pt) 2019-12-10
EP2245029A1 (en) 2010-11-03
EP2245029B1 (en) 2015-04-15
MA32150B1 (ar) 2011-03-01
TWI457338B (zh) 2014-10-21
UA105000C2 (uk) 2014-04-10
TW200942534A (en) 2009-10-16
ZA201005725B (en) 2011-04-28
EA022797B1 (ru) 2016-03-31
CA2715947C (en) 2016-10-25
PE20091473A1 (es) 2009-10-23
MY156317A (en) 2016-02-15
CN102007123A (zh) 2011-04-06
CU23890B1 (es) 2013-04-19
CL2009000381A1 (es) 2010-09-10
WO2009103739A1 (en) 2009-08-27
CA2715947A1 (en) 2009-08-27
US8049016B2 (en) 2011-11-01
IL207578A (en) 2014-11-30
US20090264444A1 (en) 2009-10-22
SV2010003650A (es) 2011-07-05
AR070429A1 (es) 2010-04-07
JP5507474B2 (ja) 2014-05-28
MX2010009158A (es) 2010-09-24
NZ587350A (en) 2012-07-27
ECSP10010411A (es) 2010-09-30
CN102007123B (zh) 2014-04-30
JP2011512384A (ja) 2011-04-21
HN2010001647A (es) 2013-11-11
IL207578A0 (en) 2010-12-30
US8318949B2 (en) 2012-11-27
EA201001315A1 (ru) 2011-06-30
AU2009216769A1 (en) 2009-08-27
CR11629A (es) 2010-11-16
JP2014132025A (ja) 2014-07-17
HK1144808A1 (en) 2011-03-11
JP5813162B2 (ja) 2015-11-17
US20120014906A1 (en) 2012-01-19
CU20100170A7 (es) 2011-10-31
KR20100117677A (ko) 2010-11-03
KR101584826B1 (ko) 2016-01-18
CO6290655A2 (es) 2011-06-20

Similar Documents

Publication Publication Date Title
JO3014B1 (ar) مثبط متغاير الحلقات للإنزيم المحدد لدرجة التخليق الحيوي للأحماض الدهنية غير المشبعة
MX2009006728A (es) Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
MY153263A (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
WO2009156484A3 (en) Organic compounds
MX2009003080A (es) Compuestos organicos heterociclicos.
WO2007143597A3 (en) Organic compounds
TN2010000203A1 (en) Beta-lactamase inhibitors
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
TN2012000085A1 (en) Pyrazole derivatives which modulate stearoyl-coa desaturase
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
GEP20156241B (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
ZA201003352B (en) Heterocyclic derivatives as modulators of ion channels
EP2129672A4 (en) ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE
TN2010000378A1 (en) Heterocyclic inhibitors of stearoyl-coa desaturase
TN2010000598A1 (en) Organic compounds
WO2009120741A3 (en) Inhibition of trim62 activity reduces cancer cell proliferation